Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Establishing post mortem criteria for the metabolic syndrome: an autopsy based cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Supportive and non-supportive interactions in families with a type 2 diabetes patient: an integrative review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Nonalcoholic Fatty Liver Disease Impairs the Liver-Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: Hyperinsulinemia aggravates insulin resistance and cardio-vascular disease. How the insulinotropic glucagon-like peptide-1 receptor agonist liraglutide in a physiologic post-prandial setting may act on pancreatic alpha and beta-cell function in patients with coronary artery disease (CAD) and type 2 diabetes (T2DM) is less clear. Methods: Insulin resistant patients with established CAD and newly diagnosed well-controlled T2DM were recruited to a placebo-controlled, cross-over trial with two treatment periods of 12 weeks and a 2 weeks wash-out period before and in-between. Treatment was liraglutide or placebo titrated from 0.6 mg q.d. to 1.8 mg q.d. within 4 weeks and metformin titrated from 500 mg b.i.d to 1000 mg b.i.d. within 4 weeks. Before and after intervention in both 12 weeks periods insulin, C-peptide, glucose, and glucagon were measured during a meal test. Beta-cell function derived from the oral glucose tolerance setting was calculated as changes in insulin secretion per unit changes in glucose concentration (B total) and whole-body insulin resistance using ISI composite. Results: Liraglutide increased the disposition index [B total × ISI composite, by 40% (n = 24, p < 0.001)] compared to placebo. Post-prandial insulin and glucose was reduced by metformin in combination with liraglutide and differed, but not significantly different from placebo, moreover, glucagon concentration was unaffected. Additionally, insulin clearance tended to increase during liraglutide therapy (n = 26, p = 0.06). Conclusions: The insulinotropic drug liraglutide may without increasing the insulin concentration reduce postprandial glucose but not glucagon excursions and improve beta-cell function in newly diagnosed and well-controlled T2DM. Trial registration ID: NCT01595789

TidsskriftDiabetology & Metabolic Syndrome
Udgave nummer1
Sider (fra-til)42
StatusUdgivet - 31 maj 2019

ID: 57306426